Literature DB >> 1588180

G2m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b.

D M Granoff1, S J Holmes.   

Abstract

G2m(23), an allotype on IgG2 molecules, is detected in sera of about two of three Caucasians. Adults who are homozygous for G2m(23) have IgG2 antibody responses to types 14 and 18C pneumococcal polysaccharides fourfold higher than those of homozygous-negative subjects. Adults homozygous for G2m(23) also show higher IgG2 antibody responses to vaccination with Haemophilus influenzae type b (Hib) polysaccharide. Furthermore, adults heterozygous for G2m(23) show IgG2 antibody responses intermediate between responses of those homozygous-positive and homozygous-negative. In contrast, the magnitude of the IgG1 antibody responses of adults to Hib polysaccharide was similar irrespective of G2m(23) genotype status. The magnitude of the IgG antibody responses of children vaccinated with Hib polysaccharide is not affected by G2m(23) status, in part because the IgG subclass responses of children to this antigen are restricted to IgG1. Also, children show no consistent associations between G2m(23) allotype status and the risk of acquiring Hib disease or the risk of Hib vaccination failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588180     DOI: 10.1093/infdis/165-supplement_1-s66

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Genetic variants of Fcγ (GM allotypes) and the Fc-mediated effector functions in HIV-1 controllers.

Authors:  Janardan P Pandey
Journal:  J Virol       Date:  2014-06       Impact factor: 5.103

Review 2.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Antibody response to the Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in healthy and infection-prone individuals with IgG3 subclass deficiency.

Authors:  M Hahn-Zoric; M Ulanova; V Friman; J Björkander; V A Oxelius; A Lucas; L A Hanson
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

Review 4.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

5.  Immunoglobulin GM and KM genes and measles vaccine-induced humoral immunity.

Authors:  Inna G Ovsyannikova; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2017-03-06       Impact factor: 4.169

6.  Immunoglobulin GM 3 23 5,13,14 phenotype is strongly associated with IgG1 antibody responses to Plasmodium vivax vaccine candidate antigens PvMSP1-19 and PvAMA-1.

Authors:  Janardan P Pandey; Cristiane G Morais; Cor Jf Fontes; Erika M Braga
Journal:  Malar J       Date:  2010-08-09       Impact factor: 2.979

7.  Immunological parameters in girls with Turner syndrome.

Authors:  Annika E Stenberg; Lisskulla Sylvén; Carl G M Magnusson; Malou Hultcrantz
Journal:  J Negat Results Biomed       Date:  2004-11-25

8.  Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination.

Authors:  Sven Kratochvil; Paul F McKay; Amy W Chung; Stephen J Kent; Jill Gilmour; Robin J Shattock
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

9.  Unveiling the Diversity of Immunoglobulin Heavy Constant Gamma (IGHG) Gene Segments in Brazilian Populations Reveals 28 Novel Alleles and Evidence of Gene Conversion and Natural Selection.

Authors:  Verónica Calonga-Solís; Danielle Malheiros; Marcia Holsbach Beltrame; Luciana de Brito Vargas; Renata Montoro Dourado; Hellen Caroline Issler; Roseli Wassem; Maria Luiza Petzl-Erler; Danillo G Augusto
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.